CA
NZ
UK
AU
IND
US
The shares moved on light volume of about 30,000 shares, so the percentage drop may reflect a thin market rather than news. The August reset assumed no improvement in academic or pharmaceutical markets, and management reorganized its commercial team and hired a new chief …
The stock climbed on ARK buying and the AI-biology rally, then fell with peers including Twist Bioscience and 10x Genomics on October 6 to 8. The screener tags the move as news, but no new October 8 company release was found. The prior August …
Several accounts describe a one-day drop of about 18.55 percent earlier this week, pushingMarket Valuefrom about USD 11 billion to USD 9.6 billion, per published reports, with analysts split on valuation. ARK sold shares on October 5, and the CEO sold about USD 923,000 …
The stock rose on spatial biology demand, AI narratives and a legal win, then fell roughly 13 to 17 percent in a session earlier this week, per market data, before slipping again. Targets from Barclays and Deutsche Bank were raised sharply, but the average …
The healthcare sector delivered a dense stretch of corporate activity this week, spanning a billion-dollar acquisition, a discontinued late-stage trial, a cleared regulatory pathway for a rare genetic disorder, and a cluster of financing moves that tell a familiar story about whereCapitalis flowing in …
AngioDynamics (NASDAQ:ANGO) announced it would report first quarter fiscal 2027 results before the open on October 8, 2026, followed by a call at 8:00 a.m. ET. This article was written before the release, so no results are known. Published market data listed a consensus …
Biohaven (NYSE:BHVN) and Ono Pharmaceutical signed an agreement on October 8, 2026 giving Ono sole rights to develop and sell Biohaven's extracellular IgG degraders in Japan, South Korea, Taiwan and ASEAN countries. The portfolio includes lead candidate BHV-1300 and follow-on candidates BHV-1310 and BHV-1320. …
Viatris (NASDAQ:VTRS) announced on February 25, 2026 that the FDA accepted its supplemental new drug application for MR-141, phentolamine ophthalmic solution 0.75%, as a treatment for presbyopia, the age-related loss of near focusing. A supplemental application asks the agency to broaden an existing approval. …
Opus Genetics reported second quarter 2026 results on August 6, 2026. Cash and equivalents were USD 88.8 million, up from USD 45.1 million at December 31, 2025. License and collaborationRevenuefell to USD 0.8 million from USD 2.9 million, mostly reimbursement of research services under …
On September 25, 2026 Daiichi Sankyo and Merck (NYSE:MRK) announced they had voluntarily withdrawn theBiologicslicense application for ifinatamab deruxtecan, known as I-DXd, in extensive-stage small cell lung cancer after the disease worsened on or after platinum chemotherapy. The submission sought accelerated approval. A calendar …
Please wait processing your request...